Polygenic effects on the risk of Alzheimer’s disease in the Japanese population

Masataka Kikuchi; Akinori Miyashita; Norikazu Hara; Kensaku Kasuga; Yuko Saito; Shigeo Murayama; Akiyoshi Kakita; Hiroyasu Akatsu; Kouichi Ozaki; Shumpei Niida; Ryozo Kuwano; Takeshi Iwatsubo; Akihiro Nakaya; Takeshi Ikeuchi; Alzheimer’s Disease Neuroimaging Initiative; the Japanese Alzheimer’s Disease Neuroimaging Initiative

doi:10.1101/2023.10.06.23296656

Abstract

Background Polygenic effects have been proposed to account for some disease phenotypes; these effects are calculated as a polygenic risk score (PRS). This score is correlated with Alzheimer’s disease (AD)-related phenotypes, such as biomarker abnormalities and brain atrophy, and is associated with conversion from mild cognitive impairment (MCI) to AD. However, the AD PRS has been examined mainly in Europeans, and owing to differences in genetic structure and lifestyle, it is unclear whether the same relationships between the PRS and AD-related phenotypes exist in non-European populations. In this study, we calculated and evaluated the AD PRS in Japanese individuals using GWAS statistics from Europeans.

Methods In this study, we calculated the AD PRS in 504 Japanese participants (145 cognitively unimpaired (CU) participants, 220 participants with late mild cognitive impairment (MCI), and 139 patients with mild AD dementia) enrolled in the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) project. In order to evaluate the clinical value of this score, we (1) determined the polygenic effects on AD in the J-ADNI and validated it using two independent cohorts (a Japanese neuropathology (NP) cohort (n=565) and the North American ADNI (NA-ADNI) cohort (n=617)), (2) examined the AD-related phenotypes associated with the PRS, and (3) tested whether the PRS helps predict the conversion of MCI to AD.

Results The PRS using 131 SNPs had an effect independent of APOE. The PRS differentiated between CU participants and AD patients with an area under the curve (AUC) of 0.755 when combined with the APOE variants. Similar AUC was obtained when PRS calculated by the NP and NA-ADNI cohorts was applied. In MCI patients, the PRS was associated with cerebrospinal fluid phosphorylated-tau levels (β estimate = 0.235, p value = 0.026). MCI with a high PRS showed a significantly increased conversion to AD in APOE ε4 noncarriers with a hazard rate of 2.22.

Conclusions We showed that the AD PRS is useful in the Japanese population, whose genetic structure is different from that of the European population. These findings suggest that the polygenicity of AD is partially common across ethnic differences.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by a Grant-in-Aid for Scientific Research (grant numbers 20K15778 to MK, 21K07271 and 21H03537 to AM, and 22H04923 to YS) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), by grants from the Japan Agency for Medical Research and Development (AMED) (grant numbers JP21dk0207045 and JP23dk0207060 to MK, AM, KO, SN, and TI, JP23wm0525019 to MK and TI, and JP21wm0425019 to YS), by Grants-in Aid from the Research Committee of CNS Degenerative Diseases, Research on Policy Planning and Evaluation for Rare and Intractable Diseases, Health, Labour and Welfare Sciences Research Grants, the Ministry of Health, Labour and Welfare, Japan (grant number 20FC1049 to YS). The funders had no role in the study design, data collection, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The ethics committees of the University of Tokyo, Osaka University and Niigata University

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

↵# The data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (adni.loni.usc.edu). Thus, the investigators within the ADNI contributed to the design and implementation of the ADNI and/or provided data but did not participate in the analysis or the writing of this report. A complete listing of ADNI investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
↵* Data used in preparation of this article were obtained from the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) database within the National Bioscience Database Center Human Database, Japan (Research ID: hum0043.v1, 2016). Thus, the investigators within J-ADNI contributed to the design and implementation of J-ADNI and/or provided data but did not participate in the analysis or the writing of this report. A complete listing of J-ADNI investigators can be found at https://humandbs.biosciencedbc.jp/en/hum0043-j-adni-authors.